<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR640.html">Part 640
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 640.101  General requirements.
                            </h3>
                            <p class="depth1"><em>(a)</em> Heat stability test. Approximately 2 ml. of completely processed material of each lot shall not show any visible sign of gelation after heating in a 12x75 mm. stoppered glass tube at 57 [deg]C for 4 hours.</p><p class="depth1"><em>(b)</em> pH. The pH of final container material shall be 6.8 0.4 when measured in a solution diluted to 1 percent protein with 0.15 molar sodium chloride.</p><p class="depth1"><em>(c)</em> Turbidity. The product shall be free of turbidity as determined by visual inspection of final containers.</p><p class="depth1"><em>(d)</em> Date of manufacture. The date of manufacture is the date of initiating the last valid measles or poliomyelitis antibody test (Sec. 640.104(b) (2) and (3)) whichever date is earlier.</p><p class="depth1"><em>(e)</em> Labeling. In addition to complying with all applicable labeling required in this subchapter, labeling shall indicate that:</p><p class="depth2"><em>(1)</em> There is no prescribed potency for viral hepatitis antibodies.</p><p class="depth2"><em>(2)</em> The product is not recommended for intravenous administration.
[38 FR 32089, Nov. 20, 1973; 48 FR 13026, Mar. 29, 1983, as amended at 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 51 FR 15611, Apr. 25, 1986; 55 FR 11013, Mar. 26, 1990; 63 FR 16685, Apr. 6, 1998; 64 FR 26287, May 14, 1999]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
